Phantagox Productions, LLC
Authentic stories and expert strategies for success in myopia management
Phantagox Productions is dedicated to telling meaningful stories with authenticity through content creation, education, and live events. Through our podcast and brand, The Myopia Mindset, we share the insights, strategies, and real-world experiences that lead to success in myopia management.
Dr. Shefali Miglani is one of the most successful myopia doctors I know, and she opened our conversation by telling me she failed. She presented the lens, the tech and the topography map, and parents walked out without signing up.
AI that predicts ten years of eye growth from one retinal photo. Our panel on Dr. David Ng's report from Vision China 2026 — and what it says about how far behind we are.
This is one of three stories from this month's Myopia News Monthly, alongside a study on late-onset myopia in high schoolers and a new RCT on red light therapy.
Full episode: myopiamindset.substack.com
Dr. Jennifer Lyerly walks through the STAR study numbers, the parents who just want the glasses, and the 25-year-old nobody knows what to do with.
Dr. Carrie Hartigan on building a pediatric-only practice, training a myopia coordinator, winning pediatrician referrals, and why one flat fee changed how she treats every kid.
Dr. David Ng was a happy general practice OD in 2002. Then he put a retinoscope in front of his three-year-old son.
The AMA takes a stand on myopia. When does the back optic zone actually matter? Sydnexis gets a second shot.
Dr. Cary Herzberg on why the surprise rejection stung, what the advisory committee will weigh, and why an approved drop changes everything for preventive eye care.
He inherited a handful of poorly-fit ortho-K patients, gave himself six months to master the specialty, and ended up co-founding a lens design company. Dr. Sukh Gill returns for a deep-dive interview.
Here’s a question Dr. Cary Herzberg wants every optometrist to ask in the mirror: if you dropped every vision care plan tomorrow, could your practice survive?
The "high myopia as disease" debate, atropine + ortho-k combo therapy, and axial length as standard of care.